1. Home
  2. News
  3. Cynata Therapeutics Limited
  4. Last Visit in GvHD Trial Completed
More Cynata Therapeutics Limited news
Cynata Therapeutics LimitedASX: CYP

Last Visit in GvHD Trial Completed

Mar 29, 2026 at 10:19 PM EDT · Issued by Cynata Therapeutics Limited

Filed with ASX · Mar 29, 2026 at 10:19 PM EDT · 2 pages · English

On 6ix: 6ix.com/news/last-visit-in-gvhd-trial-completed

Cynata Therapeutics Limited on 6ix

Story so far

  • Final Patient Visit Complete in Phase 3 Osteoarthritis TrialNov 24, 2025
  • First Patient Treated in Phase 2 GvHD TrialMar 5, 2024

Earlier from Cynata Therapeutics

  • Appendix 4D & Half-Year Financial StatementsFeb 26
  • December 2025 Quarterly Activity Report and Appendix 4CJan 28
  • Cynata Completes $1.2m At-The-Market RaiseJan 23
  • Patient Enrolment Complete in Phase 2 aGvHD Clinical TrialDec 14, 2025
  • Patient Enrolment Completed in Phase 2 aGvHD Clinical TrialDec 14, 2025

Later from Cynata Therapeutics

  • March 2026 Quarterly Activity Report & Appendix 4CApr 30
  • Cynata Secures Commitments for $1.5m PlacementMay 3
  • EU Positive Opinion on CYP-001 Paediatric Investigation PlanJun 2
  • Suspension from QuotationJun 15
  • CYP-001 GvHD Trial Primary Evaluation ResultsJun 16
All Cynata Therapeutics news releases↗

Follow Cynata Therapeutics into a list and get an email when it puts out news.

Follow Cynata Therapeutics
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer